Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01C HYPOTHALAMIC HORMONES
H01CB Somatostatin and analogues
H01CB03 Lanreotide
D04666 Lanreotide acetate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Lanreotide
D04666 Lanreotide acetate (JAN/USAN)
Hormonal Agents, Suppressant (Pituitary)
Lanreotide
D04666 Lanreotide acetate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
24 Hormones
249 Miscellaneous
2499 Others
D04666 Lanreotide acetate (JAN/USAN)
Drug groups [BR:br08330]
Hormonal agent
DG01588 Somatostatin receptor agonist
D04666 Lanreotide acetate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Somatostatin
SSTR2
D04666 Lanreotide acetate (JAN/USAN) <JP/US>
SSTR5
D04666 Lanreotide acetate (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04666
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04666
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04666